Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended A trucker in his late 70s who can't ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Scholar Rock said its investigational therapy helped preserve lean mass among patients taking a powerful weight loss drug.

Eli Lilly stock price target maintained at $1,100 on strong Zepbound sales. Analyst Ratings. Published 06/16/2025, 09:25 AM. Eli Lilly stock price target maintained at $1,100 on strong Zepbound sales.

Reuters. FILE PHOTO: The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018.

(Reuters) -Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

INDIANAPOLIS, June 16, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in ...

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...